Individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or those with severe gastrointestinal issues should avoid Semaglutide
Step-by-step: drawing 2.4 mg with a U-100 insulin syringe This protocol assumes a 10 mg/mL pre-mixed vial and a 0.5 mL U-100 insulin syringe (the most common setup for 2.4 mg dosing)
In the subgroups of patients with T2DM and received SEM as the third-line therapy (add-on to MET + TZD or MET + SU), treatment with either dose of SEM for 30 weeks to 56 weeks was associated with greater reduction in BMI, compared with SIT, EXE, or IG (Table 32)
Following the May 1, 2026 authorization of a second generic, from Apotex, seven other generic semaglutide submissions from different companies remain under review, with regulatory decisions expected in the coming weeks and months [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]
B., Hong, J
This does not change the total amount of medication (10 mg), but it does change how much liquid you have to draw up for a specific dose